Business Context and Reporting Period
Compugen Ltd. (NASDAQ: CGEN), a biotechnology company focused on computational biology, chemistry, and medicine, filed a Form 6-K on November 19, 2002, reporting financial results for the third quarter ended September 30, 2002. The filing incorporates a press release issued on October 24, 2002.
Key Financial Metrics
| Metric | Q3 2002 | Q3 2001 | 9 Months 2002 | 9 Months 2001 |
|---|---|---|---|---|
| Total Revenues | $2.8 million | $3.1 million | $8.4 million | $8.3 million |
| Net Loss | $3.0 million ($0.11/share) | $3.5 million ($0.14/share) | $9.0 million ($0.34/share) | $11.0 million ($0.42/share) |
| R&D Expenses (excl. deferred comp.) | $3.5 million | $3.5 million | $9.9 million | $10.9 million |
| Cash and Equivalents (Sept 30, 2002) | $70.6 million (Total cash, deposits, and bonds) |
Liquidity: As of September 30, 2002, the company held $58.9 million in cash, cash equivalents, and short-term investments, plus $11.7 million in long-term cash deposits and corporate bonds. Total current liabilities were $6.9 million.
Material Changes vs. Prior Period
- Revenue: Q3 2002 revenue decreased 10% year-over-year, though R&D grants increased significantly from $215,000 to $459,000. Nine-month revenue increased slightly by 1%.
- Profitability: Net loss improved by 14% in Q3 and 18% for the nine-month period compared to 2001, driven largely by a reduction in non-cash amortization of deferred compensation ($195,000 in Q3 2002 vs. $577,000 in Q3 2001).
- Expenses: R&D expenses (excluding deferred compensation) remained flat for the quarter but decreased 9% for the nine-month period. Sales and marketing expenses decreased 14% for the nine-month period.
- Cash Position: Total cash and investments decreased $7.9 million from December 31, 2001, but increased $0.4 million from the previous quarter (June 30, 2002).
Guidance, Outlook, and Risks
Updated 2002 Guidance: Compugen revised its full-year 2002 guidance downward for revenue and R&D spending, while improving the outlook for net loss and year-end cash.
- Revenue: Revised to $10-$12 million (previously $11-$13 million).
- R&D Spending: Revised to $13-$14 million (previously $16-$17 million).
- Net Loss: Revised to $12-$14 million (previously $17-$19 million).
- Year-End Cash: Revised to approximately $65 million (previously $60 million).
Management Commentary: The company highlighted progress in three key areas: computational biology, chemistry, and medicine. Key developments include an expanded collaboration with Novartis involving an RNA interference (RNAi) platform and the web launch of the Gencarta database.
Risks: Forward-looking statements are subject to risks including changes in collaborator relationships, competitive products, technological changes, and the ability to retain customers.
Investor Verification Checklist
- Verify the sustainability of the $459,000 in R&D grants received in Q3 2002, which represented a significant portion of quarterly revenue.
- Confirm the impact of the reduced R&D spending guidance ($13-$14M) on the company's ability to maintain its competitive edge in computational drug discovery.
- Monitor the execution of the expanded Novartis collaboration and the commercial uptake of the newly web-launched Gencarta product.
- Assess the company's cash burn rate relative to the revised year-end cash guidance of $65 million.